Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01278095 | Oral Bioavailability of GLPG0555 in Different Solid Formulations | PHASE1 | COMPLETED | 12 | — | — | Jan 1, 2011 | Mar 1, 2011 | Mar 24, 2011 | 1 | Belgium |
| Arm | Type | Description |
|---|---|---|
| GLPG0555 solid dispersion, fasting | EXPERIMENTAL | 50 mg as solid dispersion capsule, in fasting condition |
| GLPG0555 solid dispersion, fed | EXPERIMENTAL | 50 mg as solid dispersion capsule, after breakfast |
| GLPG0555 nanosuspension, fed | EXPERIMENTAL | 50 mg as nanosuspension, given after breakfast |
| Name | Type | Description |
|---|---|---|
| GLPG0555 solid dispersion | DRUG | solid dispersion capsules, 50 mg, single dose |
| GLPG0555 nanosuspension | DRUG | Nanosuspension, 50 mg, single dose |
Inclusion Criteria: * healthy male * BMI between 18-30 kg/m², inclusive. Exclusion Criteria: * significantly abnormal platelet function or coagulopathy * smoking * drug or alcohol abuse